1-Ross J.S, Jemings T. A, Nazeer T, Shechan Ch. E, Fisher H.A.G, Kauffman R.A, et al. Prognostic Factors in prostate cancer. Am J Clin Pathol. 2003 ; 120 (Suppl 1): S85- S100
2-Boring CC, Squires TS, Tong T. Cancer statistics 1991 [Published Correction appears in CA Cancer J Clin. 1991;41: 111]. CA Cancer J Clin. 1991; 41: 19-36.
3-Seidman H, Mushinski MH, Geib SK, Silverberg E.Probabilities of eventually developing or dying of cancer. CA Cancer J clin.1985;35:36-56.
4-Golblum J.R, Lamps L.W, Mckemey J.K, Myers J.L. ROSAI and ACKERMAN'S SURGICAL PATHOLOGY. 11 th ed. Philadelphia: Elsevier; 2018.
5-Mettlin CJ.Murphy GP,Ho R,et al. The National Cancer Data Base report on longitudinal observations on prostate Cancer. Cancer. 1996; 77: 2162-2166
6-Lu-Yao GL, Gneenberg R.Changes in Prostate Cancer incidence and treatment in USA. Lancet. 1994; 343: 251-254.
7-Cookson MS. Prostate Cancer: Sereening and early detection. Cancer Control. 2001; 8: 133-140
8- Tarone RE,Chu KC, Brawely OW. Implications of Stage- Specific Survival rates in assessing recent declines in Prostate Cancer Mortality rates. Epidemiology. 2000; 11: 167-170
9-Rafiemanesh H,Ghoncheh M, Salehinya H, Moham,Adian Hafshejawi A. Epidbmiology Of Prostate Cancer And Its Incidence Trends In Iran. Journal Of Sabzevar Vniverity Of Medical Sciences. 2016; 23120: 320-327.
10-Pereira R.A, Ravinal R.C, Costa R.S, Lima M.S, Tucci S, Muglia V.F, et al. Cyclin D1 expression in Prostate carcinioma. Braz J Med Biol Res. 2014; 47 (6): 515- 521.
11-Chen X, Miao Z, Divate M, Zhao Z, Cheung E. KM-express: an integrated online patient survival and gene expression analysis tool for the identification and functional characterization of prognostic markers in breast and prostate cancers. Database. 2018 Jan 1;2018
12-Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. Journal of cellular physiology. 2009 Aug;220(2):292-6.
13-Comstock CES, Revelo MP, Buncher CR, Knudsen KE. Impact of defferential cyclin D1 expression and localization in Prostate Cancer. British Journal of cancer. 2007; 96: 970-979
14-ӦZBEK E, MIZRAK B, ӦZBEK M, BÜYÜKBERBER S, DAVARCL M. Cyclin D1 Protooncogen expressiom in Prostate Cancer. Cyclin-V1 Protooncogen expression in prostate cancer. Turkish Journal of cancer. 2000; 30 (1): 15-23
15-Dunsmuir W.D, Gillett C.E, Meyer L.C,Young M.P, Corbishley C, Eeles R.A, et al. Molecular markets for Pnedicting Prostate Cancer Stage and Survival . BJV International. 2000; 86: 869-878.
16-Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clinical Cancer Research. 2000 May 1;6(5):1891-5.
17-Gupta V, Singh S, Sen R, Gill M, Sangwaiya A, Garg M, Chaudhry M. Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate. Prostate international. 2014 Jun 1;2(2):90-6.
)